Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress  by Frank, Helga et al.
Kidney International, Vol. 63 (2003), pp. 617–623
Effects of angiotensin II receptor antagonism on the renal
hemodynamic response to cardiovascular stress
HELGA FRANK, HANS-PAUL SCHOBEL, JAN VITKOWSKY, ROLAND E. SCHMIEDER,
and KARSTEN HEUSSER
Medical Clinic IV, Department of Internal Medicine, University of Erlangen-Nuremberg, Erlangen, Germany
Effects of angiotensin II receptor antagonism on the renal he- common target of renal hemodynamics to control water
modynamic response to cardiovascular stress. and sodium homeostasis. In this context, the cardiopul-
Background. To elucidate the effect of the angiotensin type 1 monary baroreflex is an important contributor to the he-(AT1) receptor antagonist (AT1RA) eprosartan (E) on renal
modynamic response for systemic and renal circulatoryhemodynamics in normotensive and borderline hypertensive
subjects, we investigated the hormonal and renal hemodynamic control, especially when the subject is in a state of volume
responses during cardiopulmonary stress testing. depletion or orthostatic stress [1]. Unloading of cardio-
Methods. In a prospective, double-blind, randomized, pla- pulmonary baroreceptors by intravascular volume deple-cebo-controlled crossover study, the effects of E on renal plasma
tion leads to an increased sympathetic efferent outflow toflow (RPF), renal blood flow (RBF), glomerular filtration rate
(GFR), and the concentration of angiotensin II (Ang II) levels the effector organs such as heart, kidneys and resistance
were measured with the subjects at rest and during perturbation vessels [2]. Furthermore, sustained deactivation of cardio-
of cardiopulmonary baroreceptors using lower body negative pulmonary baroreceptors by lower body negative pres-pressure (LBNP). Ten normotensive male subjects (NT) versus
sure (LBNP) causes a significant reduction of glomeru-14 males with mild hypertension (HT), matched for age and
lar filtration rate (GFR) and filtration fraction (FF), withbody mass index, who were all free of any medication, were ran-
domly assigned to receive placebo or E 600 mg/day PO for seven maintenance of effective renal plasma flow (RPF) in
days (intake phase 1). After a washout period of four weeks healthy men [3].
the subjects started the intake of the other substance for seven
The early state of arterial hypertension is character-days in a crossover manner (intake phase 2). The measurements
ized by an augmented sensitivity of the cardiopulmonarywere taken on day 7 of both intake phases.
Results. During the LBNP test, RPF and RBF were reduced baroreflex together with an increase in central blood vol-
significantly in all subjects; GFR, however, decreased significantly ume [4]. This suggests that the disturbance in renal hemo-
during cardiopulmonary stress testing in the subjects taking
dynamics and sodium and water regulation is condi-the placebo (P 0.05) and remained unchanged in those under
tioned by an altered interaction of the RAS and thetreatment with AT1RA. Ang II levels increased significantly dur-
ing cardiopulmonary stress test only in the subjects with hyper- sympathetic nerve system.
tension who were on placebo, whereas the Ang II levels did Inhibition of the RAS by angiotensin II type 1 receptor
not change in normotensive subjects or those treated with the antagonists (AT1RA) has been shown to be effective inAT1RA.
the treatment of arterial hypertension [5]. Concerning theConclusions. The data confirm that with cardiovascular stress
simulating orthostasis or volume depletion, subjects with AT1RA effect on renal hemodynamics, experimental data showed
can maintain their GFR level, suggesting that AT1RA poten- a decrease of renal vascular resistance under AT1RA in
tially is renoprotective. Additionally, the neurohumoral system
the isolated perfused kidney [6, 7]. Animal studies dem-is activated after cardiovascular stress in subjects even at an
onstrated losartan to enhance renal blood flow (RBF).early stage of hypertension.
Glomerular filtration rate (GFR), however, either did not
change or increased [8–10]. The systemic and renal hemo-Blood pressure regulation is strongly affected by a
dynamic effects of eprosartan in healthy normotensivecomplex interaction between the renin-angiotensin sys-
subjects showed a dose dependent fall in arterial bloodtem (RAS) and the sympathetic nervous system, with the
pressure and a slight renal vasodilator effect, whereas
renal clearance tests were unchanged and filtration frac-Key words: renal hemodynamics, AT1 antagonism, cardiopulmonary
tion decreased [11].stress, hypertension, blood pressure, neurohumoral system, water ho-
meostasis. The impact of AT1RA on renal hemodynamics and
the neurohumoral response during orthostatic stress sim-Received for publication June 19, 2002
ulated by LBNP, a frequent cardiovascular stress factor,and in revised form August 21, 2002
Accepted for publication September 12, 2002 is not clear. Furthermore, the effects of antagonizing the
augmented neurohumoral response to orthostatic stress 2003 by the International Society of Nephrology
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by AT1RA in hypertension are unknown. In this setting, The sequence of the placebo and drug periods was ran-
domized for the normotensive and hypertensive studythe role of a disturbed neurohumoral and sympathetic
interaction for the pathomechanism even in an early cohort separately. Pill counts were performed to ensure
compliance which was 95%. Measurements of renalstage of hypertension is yet to be elucidated.
Therefore, the aims of the present study were (1) to and systemic hemodynamics and endocrine parameters
were performed at day 7 of both intake phases; testsstudy the effects of AT1RA on renal hemodynamics; (2)
to examine the effects of cardiopulmonary baroreflex started two hours after the last intake of drug or placebo,
respectively.unloading on renal hemodynamics and neurohumoral
activity; (3) to investigate the effects of AT1RA on renal
Measurement of systemic and renal hemodynamicshemodynamics and activity of RAS during orthostatic
Systolic and diastolic blood pressure was measuredstress testing; and (4) to prove differences of renal hemo-
noninvasively beat to beat by a photoplethysmographicdynamic and neurohumoral responses to cardiovascular
finger device (Finapres; Ohmeda, Englewood, CO, USA)stress in normotensive and mildly hypertensive patients.
as described in detail [12]. Central venous pressure (CVP)
was measured by a 16-gauge indwelling catheter insertedMETHODS
through an antecubital vein and advanced to the superior
Study cohorts vena cava. Careful determination of the gain as well
Twenty-four white males without any clinical or labo- as adjustment of the pressure transducer to heart level
ratory evidence of heart, liver, kidney or endocrine dis- ensured precise absolute values. Measurements of renal
eases were included in this prospective, double-blind, and systemic hemodynamics and endocrine parameters
placebo-controlled study. In a screening phase the sub- were made at rest and under cardiovascular stress testing.
jects were classified as normotensive (NT; N  10) and Glomerular filtration rate (GFR) was assessed by the
mildly hypertensive (HT, N  14) based on four casual determination of inulin (IN) clearance and renal plasma
blood pressure readings with a standard sphygmoma- flow (RPF) by the para-aminohippuric acid (PAH) clear-
nometer at different times, with the subject sitting after ance. The filtration fraction (FF) was calculated as the
five minutes of rest. Normotension was defined by aver- quotient of clearance of IN/clearance of PAH.
age casual blood pressure readings 140/90 mm Hg, Clearances of IN and PAH were determined by the con-
mild hypertension was assumed with an average blood stant infusion technique without urine sampling [13]. Un-
pressure value of 140/90 mm Hg and 160/95 mm Hg. der steady state conditions the excreted amounts of IN
Exclusion criteria were secondary hypertensive organ (Inutest; Linz, Austria) and PAH (Nephrotest; Merck,
damage according to World Health Organization (WHO) Sharp and Dohme, Hoddesdon, UK) were equal to the
stage II or more as well as secondary forms of hyperten- infused doses of each indicator. By this assumption, the
sion, any alcohol or nicotine consumption, or any current following equation can be set:
medication. Salt restriction was not practiced. All study
GFR (mL/min)  rate of infusion (mg/min)/P (mg/mL)
participants were students and received the customary
where P is the plasma concentration of each indicator.catering at the Friedrich Alexander University campus.
This technique has proven to be a valid and reliableThe mean age of the subjects was 27.9  4.3 years (NT)
method to determine renal hemodynamics [13] withoutand 26.4  4.0 years (HT; P  NS). Their mean weight
the necessity of spontaneous urine voiding or bladder cath-and body mass index was 74.5  7.5 kg and 23.0  1.8
eterization, which alter the hemodynamic measurements.kg/m2 (NT) and 80.4  12.4 kg and 24.3  2.6 kg/m2
Since PAH is not excreted completely, this method over-(HT), respectively (NS). A complete physical examina-
estimates the true PAH clearance by approximately 10tion, laboratory tests [comprised of electrolytes, creati-
to 20% [14]. However, this bias is constant, since the ex-nine, blood urea nitrogen (BUN), liver enzymes, red and
traction of PAH is approximately 90% and similar in thewhite blood cell count], including urine tests and an
case of a renal plasma flow greater than 300 mL/min.electrocardiogram, were performed before inclusion. Se-
A central venous catheter was inserted via the left ver-rum creatinine was normal in all subjects. The study pro-
sus basilica for the infusion of both indicators, and antocol was approved by the Ethical Committee of the
intravenous line at the opposite arm was applied for with-University of Erlangen-Nuremberg, and written informed
drawing blood samples. A bolus injection of both indi-consent was obtained from each subject.
cators (18 mg PAH/kg, 45 mg IN/kg) was given over 15
Study design minutes at which the bolus dose has been calculated
Normotensive and hypertensive subjects received ei- according to the distribution volumes of both indicators
[15]. Subsequently, a constant infusion dose of both sub-ther placebo for seven days, followed by a washout pe-
riod of four weeks and thereafter eprosartan (E) 600 mg stances was calculated (0.75 g/h PAH, 1.5 g/h IN) assum-
ing a normal creatinine clearance and a continuous infu-once a day orally for another seven days, or the sequence
of placebo and E was reversed in a crossover manner. sion was started. PAH concentrations were measured by
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Table 1. Baseline characteristics of subjects with normotension
and mild hypertension
NT (N  10) HT (N  14) P
Age years 27.94 26.44 NS
Body mass index kg/m2 231.8 24.32.6 NS
RR casual
Systolic mm Hg 12510 14210 0.05
Diastolic mm Hg 744 828 0.01
RR 24 hours
Systolic mm Hg 1259 13210 0.05
Diastolic mm Hg 734 888 0.05
Heart rate min1 607 627 NS
Central venous pressure
mm Hg 71.8 7.21.6 NS
RPF mL/min 60467 54868 0.05
Fig. 1. Experimental device for the lower body negative pressure GFR mL/min 11010 11212 NS
(LBNP) test. Filtration fraction % 18 20 NS
Angiotensin II
concentration ng/mL 6.62.5 7.22.9 NS
the method of Pratton and Marshall as modified by Smith
Abbreviations are: NT, normotensive subjects; HT, mild hypertensive subjects;et al [16]. IN was measured indirectly by converting IN RR, 140/90 mm Hg and 160/95 mm Hg; RPF, renal plasma flow; GFR,
glomerular filtration rate; FF, filtration rate; NS, not significant.into fructose and subsequently measuring fructose by
an enzymatic method (716260; Boehringer Mannheim,
Mannheim, Germany). The filtration fraction (FF) was RESULTS
calculated by dividing the GFR by the RPF.
Subject characteristics as well as baseline renal and
Lower body negative pressure test systemic hemodynamics and angiotensin II levels are
presented in Table 1. Effects of AT1RA on renal andEach subject was submitted to a negative pressure de-
systemic hemodynamics are shown in Table 2 and re-vice consisting of an airtight box in which the lower half
sponses of systemic and renal hemodynamics to LBNPof the body down from the iliac crests was inside. The
are presented in Table 3. The effects of AT1RA on thesubjects remained in a supine position during the entire
study period. The vacuum in the box was achieved by renal hemodynamic response to orthostatic stress is shown
the use of a standard vacuum cleaner motor and the in Figure 2 and on endocrine parameters in Figure 3.
level of the vacuum was continuously measured by a
AT1RA effect on blood pressurestandard mercury manometer connected to the inside of
the box. Each subject was submitted to a level of 15 Systolic and diastolic blood pressure was significantly
mm Hg for 30 minutes. The target level was achieved higher in the group of HT (142  10/82  8 mm Hg)
within 5 seconds. Measurements of systemic and renal compared to the group of NT (125  10/74  4 mm Hg,
hemodynamics and endocrine parameters were per- P  0.05) at the beginning of the study. Under AT1RA,
formed under steady state conditions after at least 20 blood pressure decreased significantly in HT by 7  2
minutes of LBNP. Symptoms such as syncope or vertigo mm Hg (systolic) and by 4  2 mm Hg (diastolic, P 
did not occur. The experimental LBNP device is shown 0.05), whereas in NT there was no change of systolic or
in Figure 1. diastolic blood pressure under AT1RA (105  10/54 
5 vs. 109  14/57  9 mm Hg under placebo; NS).Endocrine parameters
Blood samples to measure angiotensin II (Ang II) AT1RA effect on systemic and renal hemodynamics
levels were placed into prechilled tubes, immediately
Renal plasma flow was significantly lower in subjectscentrifuged at 0C and stored for final evaluation at
with mild hypertension (548  68 mL/min) compared to
18C. All samples were analyzed within three months
normotensive subjects (604  67 mL/min, P  0.05) atof storage. Plasma concentrations of Ang II were deter-
rest, whereas GFR was not different in both groups. Formined by radioimmunoassay [17].
those taking the AT1RA, RPF increased significantly in
normotensive subjects (681  117 vs. 604  67 mL/Statistical analysis
min under placebo, P  0.05) as well as in hypertensiveAll results are presented as means  standard devia-
subjects (632  84 vs. 548  68 mL/min with placebo,tion. All data were analyzed by using the SPSS/PC ver-
P  0.05). This increase of RPF under AT1RA wassion of the statistics package for social sciences [18].
greater in HT than in NT (P  0.01, Table 2).Two-way analysis of variance (ANOVA) for repeated
A slight, but not significant rise in GFR was observedmeasurement design and the Student paired and un-
only for the total study group (114  13 vs. 111  11paired t tests (normotensive vs. hypertensive subjects)
mL/min under placebo, P  0.07). However, in eachwere used when indicated. Values with a P  0.05 were
considered as statistically significant. group separately, no change of GFR could be found.
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Table 2. Effects of eprosartan on systemic and renal hemodynamics
in NT (N  10) vs. HT (N  14)
Parameter NT HT P
HR bpm 10.5 57 0.05
SAP mm Hg 41.4 716 0.05
DAP mm Hg 40.8 31.5 NS
CVP mm Hg 	0.50.3 	0.80.5 NS
RPF mL/min 	7726 	8411 0.01
GFR mL/min 	31.1 	41.2 NS
FF % 	20.3 	20.5 NS
Values are means SD and are expressed as changes from baseline. Abbrevia-
tions are: NT, normotensives; HT, mild hypertensives; HR, heart rate; SAP/
DAP, systolic/diastolic arterial pressure; CVP, central venous pressure; RPF, Fig. 2. Effects of angiotensin II type 1 receptor antagonist (AT1RA)
renal plasma flow; GFR, glomerular filtration rate; FF, filtration fraction.
with placebo () and eprosartan ( ) on the renal hemodynamic response
to LBNP.
Table 3. Effects of LBNP (15 mm Hg) on systemic and renal
hemodynamics in the entire group (NT 	 HT, N  24) found between the group of NT and HT under AT1RA
Parameter Rest LBNP P (RPF 18  33 mL/min in NT vs. 20  26 mL/
min in BHT; NS). The LBNP-induced decline of GFR,HR bpm 617 636 0.05
SAP mm Hg 11715 1209 0.05 however, was prevented under treatment with AT1RA.
DAP mm Hg 619 6511 0.01 Under E, GFR rose in all subjects during LBNP (GFRCVP mm Hg 7.11.3 2.81.2 0.0001
	1  3 mL/min under E vs. 2  2 mL/min underRPF mL/min 57573 54075 0.01
GFR mL/min 11011 10810 0.01 placebo). This GFR-maintaining effect of E during car-
FF % 191 192 NS diovascular stress was significant (P  0.01) and similar
Abbreviations are: NT, normortensives; HT, mild hypertensives; HR, heart in the group of NT and HT.rate; SAP/DAP, systolic/diastolic arterial pressure; CVP, central venous pressure;
RPF, renal plasma flow; GFR, glomerular filtration rate; FF, filtration fraction.
Effects of AT1RA and LBNP on endocrine parameters
Under treatment with E, plasma Ang II levels in-
Filtration fraction did not change under therapy with creased significantly in all subjects (P  0.001). At a
AT1RA either in normotensives (0.16 vs. 0.18 under LBNP level of 15 mm Hg, a significant rise of plasma
placebo) or in subjects with mild hypertension (0.18 vs. Ang II levels (P  0.001) was noticed in all subjects.
0.20 under placebo; NS). However, this increase during LBNP was significantly
enhanced in the group of HT compared to the group ofEffect of LBNP on systemic and renal hemodynamics
NT (P  0.05; Fig. 3).
At a LBNP level of 15 mm Hg, central venous pres-
sure fell significantly (P  0.0001). Heart rate rose in all
DISCUSSIONsubjects significantly (P  0.05) and a slight increase of
systolic as well as a significant increase of diastolic blood The present study shows that there is a significantly
pressure occurred during LBNP. This systemic hemody- lower RPF in patients with mild hypertension and nor-
namic reaction was not different in NT and HT. mal renal function compared to normotensive subjects.
Lower body negative pressure led to a significant re- Interestingly, with the AT1RA administration, the RPF
duction of RPF in all subjects (P  0.01, Table 3). The rose in both groups, and this increase was significantly
renal hemodynamic responses to LBNP of NT and HT higher in hypertensive than in normotensive subjects. Un-
were not different. As well, GFR decreased significantly loading of cardiopulmonary baroreceptors significantly
under cardiopulmonary baroreflex discharge (108  10 reduced the RPF and GFR in all subjects. AT1RA pre-
vs. 110  11 mL/min at rest, P  0.05) in normotensive vented this renal hemodynamic response during cardio-
and hypertensive subjects. FF remained stable (0.19) at vascular stress testing, as during LBNP the GFR was main-
rest as well as under LBNP in all subjects. tained in both normotensive and hypertensive subjects.
Already in this early stage of hypertension, there was
AT1RA effects on renal hemodynamic response a significantly higher increase of Ang II release during
to LBNP cardiovascular stress with the LBNP compared to nor-
The effects of E on renal hemodynamics during un- motensive subjects.
loading of the cardiopulmonary baroreflex are presented
Effects of AT1RA on systemic and renal hemodynamicsin Figure 2. The LBNP-induced reduction of RPF was
not influenced by the therapy with E [absolute change In accordance with earlier results [19, 20], there was
from baseline (RPF) 19  29 mL/min vs. 16  21 a significant decrease of blood pressure in the mildly hy-
pertensive subjects under AT1RA therapy. In addition,mL/min under placebo; NS]; no significant difference was
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Fig. 3. Effects of AT1RA on angiotensin II
release with eprosartan and LBNP. Abbrevia-
tions are: NT, normotension; HT, mild hyper-
tensives; E, eprosartan; Ang II, angiotensin II
levels (ng/L).
eprosartan, a representative of the class of AT1RA typi- administration was more marked, with a highly signifi-
cant increase of RPF than found in normotensive sub-fied with a carboxy benzyl imidazole acrylic acid, has
been shown to exert central sympathoinhibitory effects jects. This surplus effect could be due to the striking
effect of the AT1 receptor blockade, with relatively moreby blocking the presynaptic AT1 receptors promoting
sympathetic nerve activity [19, 21]. However, in normo- substantial vasodilating actions occurring in conditions
of a stimulated renin-angiotensin system, like hyperten-tensive subjects the blood pressure levels decreased only
slightly during the E administration in our study. This sion [24], compared to a state of balanced renin-angio-
tensin system, such as is found in normotension.could be explained statistically by the small number of
study subjects and also by the fact that E may have
Systemic and renal hemodynamic response to LBNPsympathoinhibitory effects, especially in a state of an
with and without AT1RAactivated sympathetic nervous system as hypertension.
Only few clinical data exist on renal hemodynamic Our studies clearly demonstrate that deactivation of
effects of AT1RA. In normotensive subjects, AT1RA the cardiopulmonary baroreflex by LBNP, substantiated
have been shown to have no effect on the GFR, and to by a significant fall of central venous pressure and thus
induce either no change or a modest increase in RBF simulating orthostatic stress, leads to both a systemic and
[22, 23]. Price et al’s study of healthy men who were on a regional hemodynamic response, as shown by the de-
a low salt diet and given E orally, demonstrated renal crease of RPF. These effects, together with the LBNP-
vasodilator effects of a significant rise of RPF. Glomeru- induced increase of Ang II, prove that the interaction
lar filtration rate did not change and a significant de- between the sympathetic nervous system and the RAS
crease of filtration fraction was noted. The decrease of exists in the regulation of blood pressure and volume
RPF as a renal hemodynamic response to exogenous homeostasis.
Ang II was blunted by an oral administration of E at a In agreement with previous studies [25, 26], a LBNP
dose of 200 mg, as there was a renewed increase of RPF; level of 15 mm Hg in our study caused no fall of blood
this indicates that a parallel shift of the dose-response pressure, but a significant increase of diastolic and a
curve occurred, thus supporting the concept that E acts slight increase of systolic blood pressure were noted.
as a competitive antagonist [11]. Our objective was to This result may be explained by the acute activation of
assess the renal hemodynamic response not only in nor- the renin-angiotensin system, which has been verified
motensive subjects, but also in patients with mild hyper- for normal subjects during unloading of the cardiopul-
tension. Our hypothesis that E antagonizes the aug- monary baroreflex [27–29]. The increase of heart rate in
mented neurohumoral response in the kidneys in the all subjects can be assumed to be a consequence of reflex
state of early hypertension is confirmed. sympatho-excitatory response to deactivated atrial baro-
receptors, as demonstrated earlier by the microneuro-We found a significantly reduced RPF in the patients
with mild hypertension and normal renal function. The graphic measurements by Sundlof and Wallin [30].
In our study, a continuous LBNP level of15 mm Hgreason for this finding may be that the renin-angiotensin
system is stimulated in this state of mild hypertension caused a significant decline of RPF and GFR in all sub-
jects, suggesting that this cardiovascular stress-simulat-[24], with a vasoconstrictive action located at the afferent
glomerular arteriole. Remarkably, in mildly hyperten- ing orthostasis leads to an enhancement of renal vascular
resistance caused by an increased sympathetic outflowsive subjects the renal vasodilator effect after AT1RA
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and/or an effect of an increased Ang II release. However, in hypertensive subjects, pointing to an excessive synthe-
sis of Ang II in the unique situation of sympathetic stimu-previous studies showed only little alterations of renal
lation by mental stress. Yet, in comparison with thesevascular resistance in healthy subjects at lower levels of
former findings, cardiopulmonary stress testing by LBNPLBNP (20 mm Hg) [27, 28]. Wu¨rzner et al found no
caused a decrease of GFR in all subjects, indicating achanges in renal hemodynamics in normal subjects up
vasoconstriction in the renal vascular bed. The renalto a LBNP level at 22.5 mm Hg [31]. At higher levels,
hemodynamic response in this setting is similar to reac-a trend toward a decrease in GFR and RPF was seen.
tions during physical stress and aerobic exercise that areAs well, splanchnic vascular resistance has been shown
known to lead to a decrease in GFR [35].to rise only at high levels of LBNP [32], whereas forearm
This finding of a sustained GFR during LBNP bymuscle vascular resistance increases during selective un-
AT1RA could be a useful clinical action in situations of
loading of cardiopulmonary baroreceptors by lower lev- intravascular volume depletion or heart failure with re-
els of LBNP [33]. Therefore, the threshold for each car- duced renal perfusion, and implicate AT1RA as being
diopulmonary and arterial baroreceptor deactivation renoprotective in clinical states that are affected with a
and the equivalent LBNP level are not clearly defined. high risk of acute renal failure.
Experimental data demonstrated a close relationship
Effect of LBNP and AT1RA on endocrine parametersbetween decreases in RPF and elevations of Ang II con-
centrations in the isolated perfused rat kidney [34]. Our As expected and also documenting the validity of our
data confirm this association of decreased RPF and stim- data, we observed a rise of Ang II concentrations in
ulated circulating Ang II during cardiopulmonary baro- all subjects under AT1RA. In several earlier studies,
Burnier et al demonstrated that a competitive angioten-reflex discharge.
sin receptor blocker induces a compensatory increasedIt is remarkable that no difference of the hemody-
release of Ang II [36, 37]. In agreement with previousnamic pressure response to LBNP in normotensive and
data, we found no difference in the enhanced Ang IImild hypertensive subjects was seen, suggesting that the
release in normotensive and hypertensive subjects underneural circulatory reflex response is similar in both groups.
AT1RA [38].Of note, in our study, therapy with AT1RA preserved
Our data confirm that the baroreflex discharge bythe decrease of GFR as a renal circulatory response to
LBNP leads to a significant increase of Ang II levels asLBNP in all subjects. AT1RA raised RPF at rest; how-
well. Decreased venous return to the heart caused byever, under cardiovascular stress RPF decreased. The
LBNP acts as a stimulus for the juxtaglomerular cellsRPF response to LBNP did not change after AT1RA
via sympathetic nerve control to raise the circulating
administration. These dissociations may illustrate that a Ang II. Tidgren et al studied 10 healthy volunteers and
subset of endocrine and neural mechanisms influence likewise demonstrated that LBNP administered with
renal hemodynamic autoregulation differentially during stepwise increases up to 40 cm H2O enhances circu-
cardiovascular stimuli. Thus, Tidgren et al showed a di- lating angiotensin II [27]. However, when the Ang II
verging release of dopamine and noradrenaline renal responses to LBNP for normotensive and mildly hyper-
overflow during LBNP [27], suggesting that a portion of tensive subjects were analyzed separately, we found a
the dopaminergic nerve participates in the control of significantly exalted reaction in the mildly hypertensive
renal circulation. Furthermore, while angiotensin con- compared to normotensive subjects. This finding empha-
verting enzyme (ACE) inhibitors block the enzymatic sizes that cardiovascular stress caused by LBNP which
imitates orthostasis induces an enhanced neurohumoraldissimilation of kinins and thus lead to an intensified
stimulation yet in mild hypertension. Thus, even in anrenal vasodilation, AT1RA does not influence the kinin
early stage of hypertension, there are hints for a dis-metabolism [11]. Hence, the renal vascular tone under
turbed neurohumoral reflex response of cardiopulmo-AT1RA is not affected by enhanced kinin concentrations
nary baroreceptor discharge.[24]. These effects could explain that, in this experimen-
Taken together, these results provide new insights intotal situation with reduced RPF as a response to LBNP,
the disturbed neurohumoral blood pressure regulationGFR does not decline further by additional effects due
in mild forms of hypertension after excessive stimulationto kinins and prostaglandins.
of RAS induced by cardiovascular stress appropriate toOur previous study examined the effects of an ACE
orthostasis. Moreover, our results show that AT1RA may
inhibitor on renal hemodynamics in 20 normotensive exert renoprotective effects in clinical situations of vol-
and 20 mildly hypertensive subjects at rest and during ume depletion by its ability to sustain GFR in a state of
mental stress [35]. In this earlier study, sympathetic acti- reduced cardiac preload.
vation during mental stress led to an increase of GFR
in both study groups, and this was more pronounced in ACKNOWLEDGMENT
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